Bone density changes from long-term tenofovir for hepatitis B
Treatments studied
Part of Bones, joints & muscles, Infections clinical trials.
This study checks whether taking tenofovir for a long time (more than five years) affects bone density in people with chronic hepatitis B. It may help doctors understand how to better monitor bone health during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have been diagnosed with chronic hepatitis B (a long-term liver infection).
- You must have been taking tenofovir disoproxil fumarate (TDF) for more than five years.
- You must not have other chronic liver diseases (besides hepatitis B).
- You must not have chronic kidney disease.
- You must not be on combination therapy (taking interferon plus a nucleoside analogue, or multiple nucleoside analogues together).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether taking tenofovir for hepatitis B for more than five years affects kidney function. If you have hepatitis B and have been on this medicine long-term, this trial will help understand if your kidneys need monitoring.
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
This study tests whether a fungus-fighting drug, terbinafine, can help treat chronic hepatitis B. It is for people with stable disease who are not on other antivirals or are only on tenofovir.
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Hear when a new Bone Density trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.